Gemcitabine-(C4-amide)-[anti-EGFR] produced greater anti-neoplastic cytotoxicity than either gemcitabine (C5-methylcarbamate)-[anti-HER2/neu] [24] or gemcitabine-(C4-amide)-[anti-HER2/neu] against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) during an 182-hour incubation period (Figure 6 and Figure 7). Here, ERBB2 is linked to breast adenocarcinoma.